• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pardes Biosciences, Inc. - Common Stock (NQ:PRDS)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 2.160 (5)
Ask (Size) 2.210 (250)
Prev. Close 2.160
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 61,716,745
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences
August 28, 2023
From Foresite Capital
Via Business Wire
News headline image
MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares
August 17, 2023
From MediPacific, Inc.
Via Business Wire

Performance

More News

Read More
News headline image
PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS
August 07, 2023
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Why Pardes Biosciences Shares Are Rising Monday ↗
July 17, 2023
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sculptor Capital Management Inc. (NYSE – SCU), Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Great Ajax Corp. (NYSE – AJX)
July 24, 2023
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS
July 21, 2023
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Recap: Pardes Biosciences Q1 Earnings ↗
May 05, 2023
Via Benzinga
News headline image
Pardes Biosciences Looks For Alternatives After Failed COVID-19 Study ↗
April 03, 2023
Via Benzinga
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Pardes Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
July 19, 2023
From The Schall Law Firm
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023 ↗
July 18, 2023
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Kaleyra, Inc. (NYSE – KLR), Great Ajax Corp. (NYSE – AJX)
July 18, 2023
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
PRDS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Pardes Biosciences, Inc. Is Fair to Shareholders
July 17, 2023
From Halper Sadeh LLC
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
April 24, 2023
Via InvestorPlace
News headline image
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
July 17, 2023
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
April 03, 2023
Via Benzinga
News headline image
Pardes Biosciences, Inc. (NASDAQ:PRDS) Investor Alert: Investigation over Potential Wrongdoing ↗
February 14, 2023
Via SBWire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023 ↗
April 04, 2023
Via Benzinga
News headline image
Investigation Announced for Investors Who Lost Money with Shares of Pardes Biosciences, Inc. (NASDAQ: PRDS) ↗
January 23, 2023
Via SBWire
News headline image
Why Quotient Shares Are Trading Lower By More Than 48%; Here Are 37 Stocks Moving Premarket ↗
December 13, 2022
Via Benzinga
News headline image
Why American Public Education Shares Are Trading Lower By Around 49%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
March 15, 2023
Via Benzinga
News headline image
Vapotherm, Redwire And These 2 Penny Stocks Insiders Are Aggressively Buying ↗
December 06, 2022
Via Benzinga
News headline image
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
January 31, 2023
Via Benzinga
News headline image
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session ↗
December 13, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022 ↗
December 13, 2022
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
November 28, 2022
Via Benzinga

Frequently Asked Questions

Is Pardes Biosciences, Inc. - Common Stock publicly traded?
Yes, Pardes Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Pardes Biosciences, Inc. - Common Stock trade on?
Pardes Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pardes Biosciences, Inc. - Common Stock?
The ticker symbol for Pardes Biosciences, Inc. - Common Stock is PRDS on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap